
![]() |
|||||||||||||
WJPR Citation
|
| All | Since 2020 | |
| Citation | 8502 | 4519 |
| h-index | 30 | 23 |
| i10-index | 227 | 96 |
BRIEF REVIEW ON MRSA AND VRSA
Deepak Bhatt*, Saugat Dahal, Rajindar Singh and Sushobhan Bhandari
Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is a bacteria that is resistant to many antibiotics. Staph and MRSA can cause a variety of problems ranging from are skin infections and sepsis to pneumonia to bloodstream infections. Vancomycin-resistant Staphylococcus aureus (VRSA) is a rare, multidrug-resistant bacterium of public health concern that emerged few decade back. Appropriate antimicrobial prescribing by healthcare providers, adherence to recommended infection control guidelines, and, ultimately, the control of both MRSA and VRSA are necessary to prevent further emergence of VRSA strains. Increased frequency of S. aureus infections imposes a high and increasing burden on healthcare resources. Methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) cause nosocomial infections and are linked with increased rates of illness and death. Common preventive measures when used by health care professional and general public help to reduce infection chances. Appropriate use of right antibiotic lead to decrease chance of evolution of drugs resistance. As of now, all MRSA and VRSA isolates have been susceptible to several Food and Drug Administration (FDA) - approved drugs. Keywords: Staphylococcus aureus, MRSA and VRSA. [Full Text Article] [Download Certificate] |
